Search Videos and More
Video
Paolo Tarantino, MD Discusses RELIEVE Study
Dana-Farber's Paolo Tarantino, MD, presented results from the RELIEVE study showing patients with metastatic breast cancer receiving trastuzumab deruxtecan fared best if they had HER2+ disease or stable HER2-low disease.
Video
Heather Parsons, MD, MPH Discusses Liquid Biopsy
Dana-Farber's Heather Parsons, MD, MPH, discusses a new study showing liquid biopsy could reliably determine whether a patient's breast cancer is HER2-positive or --negative.
News
Psilocybin Eases Depression in Patients with Cancer, Study Finds
For patients with cancer who are suffering from major depression, treatment with psilocybin plus individual and group psychological support can significantly relieve depressive symptoms, a clinical trial has found. In a companion study led by Dana-Farber Cancer Institute investigators, trial participants said the treatment experience with psilocybin – a hallucinogenic compound derived from certain mushrooms – created a sense of connection, meaning, and transcendence that aided the healing process.
News
Exploring How CAR T-Cell Therapy May Help More Patients
CAR T-cell therapy burst onto the scene as a revolutionary treatment for cancer patients in 2015, when it was introduced in clinical trials primarily for patients with lymphoma and leukemia. Since then, it has transformed the course of disease, primarily for blood cancer patients, with many clinical trials now exploring the approach for solid tumor patients. Through this highly tailored form of immune effector cell (IEC) therapy, typically a patient's own immune cells — known as T cells — are genetically re-engineered to identify and kill cancer cells.
News
Dana-Farber Research Publication 01.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Course
Topics in Gastrointestinal Oncology
This course is designed to give medical oncologists, surgeons, radiation oncologists, gastroenterologists, primary care physicians, nurses, and other interested clinicians updated information regarding the management of gastrointestinal cancers.
News
Dana-Farber Research Publication 12.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.1.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2023 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
Symposium
2023 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2023 San Antonio Breast Cancer Symposium.
News
2023 Updates in Neuro-Oncology
Please join us on Zoom for a free symposium on the latest advances in neuro-oncology. Through lecture and discussion, Harvard Medical School faculty will consider how to apply recent clinical research advances to improve the care and outcomes of patients with brain tumors.
News
Dana-Farber Research Publication 11.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.